ResMed Reports 9% Revenue Growth to $1.34 Billion in Latest Quarter

ResMed Inc. reported a net revenue of $1.34 billion for the three months ending September 30, 2025, marking a 9% increase from $1.22 billion in the same period last year. The company's gross profit rose to $820.8 million, up from $717.2 million, resulting in a gross margin of 61.5%, compared to 58.6% in the prior year. Net income for the quarter was $348.5 million, a 12% increase from $311.4 million, leading to diluted earnings per share of $2.37, up from $2.11. The increase in revenue was attributed to higher demand and unit sales in both the Sleep and Breathing Health and Residential Care Software segments.

In terms of operational metrics, ResMed's Sleep and Breathing Health segment generated $1.17 billion in revenue, a 10% increase year-over-year, while the Residential Care Software segment contributed $166.1 million, reflecting a 6% growth. The company noted that currency fluctuations positively impacted revenue by approximately $15.6 million. The U.S., Canada, and Latin America markets accounted for a significant portion of the revenue, with total sales reaching $774.8 million, a 10% increase from the previous year. The company also reported a cash and cash equivalents balance of $1.38 billion as of September 30, 2025, up from $1.21 billion at the end of June 2025.

ResMed's strategic developments included a focus on research and development, with $87.3 million invested during the quarter, representing 6.5% of net revenues. The company highlighted the launch of its new AirSense 11 device, which features advanced technology aimed at improving patient outcomes. Additionally, ResMed's workforce underwent restructuring, resulting in $15.8 million in related expenses, which were not present in the same quarter last year. The company also repurchased $150 million in treasury stock during the quarter, compared to $50 million in the prior year.

The company’s total assets increased to $8.31 billion from $8.17 billion, while total liabilities decreased to $2.19 billion from $2.21 billion. ResMed's stockholders' equity rose to $6.12 billion, up from $5.97 billion. The company reported a total debt of $668.6 million, with a significant portion attributed to its revolving credit facility and senior notes. ResMed remains in compliance with its debt covenants and has $1.5 billion available under its revolving credit facility.

Looking ahead, ResMed anticipates continued growth driven by its innovative product pipeline and expanding market presence. The company remains committed to enhancing its digital health solutions and improving patient care, while also navigating potential challenges related to macroeconomic conditions and regulatory changes. ResMed's management expressed confidence in the company's ability to sustain its growth trajectory and deliver value to shareholders in the coming quarters.